Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Optimal timing for the collection and in vitro expansion of cytotoxic CD56(+) lymphocytes from patients undergoing autologous peripheral blood stem cell transplantation
Autore:
Clausen, J; Petzer, AL; Vergeiner, B; Enk, M; Stauder, R; Gastl, G; Gunsilius, E;
Indirizzi:
Univ Innsbruck Hosp, Div Hematol & Oncol, Lab Tumor Biol & Angiogenesis, A-6020 Innsbruck, Austria Univ Innsbruck Hosp Innsbruck Austria A-6020 , A-6020 Innsbruck, Austria
Titolo Testata:
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
fascicolo: 4, volume: 10, anno: 2001,
pagine: 513 - 521
SICI:
1525-8165(200108)10:4<513:OTFTCA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
NATURAL-KILLER-CELL; COLONY-STIMULATING FACTOR; BREAST-CANCER PATIENTS; BONE-MARROW TRANSPLANTATION; SUPPRESSOR CELLS; NK CELLS; T-CELL; INTERLEUKIN-2; CHEMOTHERAPY; IMMUNOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Gunsilius, E Univ Innsbruck Hosp, Div Hematol & Oncol, Lab Tumor Biol & Angiogenesis, Anichstr 35, A-6020 Innsbruck, Austria Univ Innsbruck Hosp Anichstr 35 Innsbruck Austria A-6020 ria
Citazione:
J. Clausen et al., "Optimal timing for the collection and in vitro expansion of cytotoxic CD56(+) lymphocytes from patients undergoing autologous peripheral blood stem cell transplantation", J HEMATH ST, 10(4), 2001, pp. 513-521

Abstract

To identify the optimal time for the collection of CD56(+) cytotoxic lymphocytes for adoptive immunotherapy in patients undergoing high-dose chemotherapy (HDCT) and peripheral blood stem cell (PBSC) transplantation, 18 breast cancer patients receiving either three cycles of epirubicin/paclitaxel (CT x 3) followed by HDCT and PBSC transplantation (n = 12) or CTx6 (n = 6) were studied. Blood samples were obtained before each CT/HDCT cycle, from PBSC collections, and repeatedly after autografting for up to 12 months. The number of CD56(+)3(-) and CD56(+)3(-) lymphocytes, their in vitro expandability with interleukin-2, and their cytotoxicity against MCF-7 and Daudi cells were analyzed. Six healthy females served as controls. CD56(+) cell counts in both treatment groups were subnormal but stable during the observation period. The cytotoxicity of the expanded CD56(+) cells was normal and unaffected by the treatment. The in vitro CD56(+) cell expandability (controls, 100 +/- 31-fold, mean +/- SEM) was normal before CT1 and CT2, but reducedin PBSC harvests performed after CT2 and application of G-CSF (21 +/- 6-fold; p < 0.01). After PBSC harvesting, the CD56(+) cell expandability increased to 185 +/- 74-fold and 170 +/- 69-fold (before CT3 and HDCT). This increase was not observed in those patients who did not undergo PBSC mobilization. Two weeks after autografting, the CD56(+) cell expandability was minimal (6 +/- 1-fold), and recovered to 34 +/- 6-fold. Thus, CT, HDCT and autografting do not alter the frequency and inducible cytotoxicity of CD56(+) cells in breast cancer patients. However, the proliferative capacity of CD56(+) cells obtained from PBSC harvests and after autografting is impaired. Therefore, instead of the PBSC graft, maximally expandable CD56(+) cells obtained at least 1 week after PBSC collection should be considered for adoptiveimmunotherapy after PBSC autografting.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:47:21